Categories: Featured

AstraZeneca’s experimental thyroid cancer treatment drug is toxic, says FDA

AstraZeneca Plc’s is a thyroid cancer treatment drug has been introduced on an experimental basis. But the research conducted by the US regulators claim that the consumption of this drug may lead to ‘substantial toxicity’.

According to the information from the Food and Drug Administration (FDA) department, the medicine called “vandetanib” has been linked to severe side effects in as many as 31 percent of patients in this study.

The American Cancer Society claims that about 44,670 people in the U.S. will be diagnosed with thyroid cancer and it also states that out of which, 1,690 will die due to the disease. A type of cancer called medullary thyroid cancer develops in cells that produce calcitonin. It is a hormone that helps in metabolizing calcium.

The FDA has given Astra Zeneca a period of six months for a review programme, in order to develop some advanced drugs for the treatment of thyroid cancer.

Penelope P

Beauty aficionado who dreams of one day become a professional beauty blogger.

Share
Published by
Penelope P

Recent Posts

Virgin Galactic takes its first flight  with tourists to the edge of space

American space craft company Virgin Galactic is ready to take the first set of space…

1 year ago

FDA approves new drug to treat post-partum depression

Post-partum depression has been one of the most common problems among women and unfortunately has…

1 year ago

Ways how exercise can improve your mental health

Exercise has always been the best way to maintain physical as well as mental health.…

1 year ago

4 Habits to do every night to improve brain health

While it is a good habit to look after your body with the help of…

1 year ago

7 Things to keep in mind while consuming fruits

Fruits have their own nutrients which are essential for the body. While their consumption is…

1 year ago

Ways to deal with High Functional Anxiety

When you look around yourself, you will find people who might be successful as well…

1 year ago